Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years

Table 1 Baseline characteristics in 53 study subjects

Characteristics	n (%) or range
Mean age (years)	55 (28-80)
Age > 50 year-old	35 (66)
Male:Female	24:29 (45.3:54.7)
Ethnicity
Asian	51 (96.2)
Hispanic	1 (1.9)
Other	1 (1.9)
BMI ≥ 25 kg/m2	17 (32.1)
Clinical cirrhosis	8 (15.1)
Spleen size > 12 cm	4 (7.7)
HBV genotype
A	2/24 (8.3)
B	15/24 (62.5)
C	6/24 (25)
D	1/24 (4.2)
HBeAg +
Yes No	15 (28.3) 38 (71.7)
Mean ALT (U/L)	24.8 (7-108)
Mean AST (U/L)	25.7 (15-89)
Mean creatinine (mg/dL)	0.86 (0.5–1.7)
Mean APRI score	0.37 (0.13-0.92)
Mean FIB-4 score	1.66 (0.49-5.33)
Mean SWE score (kPa)	7.05 (4-20.9)
Platelets ≤ 120 × 109/L	6 (11.3)

BMI: Body mass index; HBV: Hepatitis B virus; HBeAg: hepatitis B e antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis-4; SWE: Shear wave elastography.